Pasithea Therapeutics (NASDAQ:KTTA) Stock Price Up 5%

Pasithea Therapeutics Corp. (NASDAQ:KTTAGet Rating) shares were up 5% during mid-day trading on Thursday . The stock traded as high as $1.07 and last traded at $1.05. Approximately 64,210 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 426,825 shares. The stock had previously closed at $1.00.

Pasithea Therapeutics Price Performance

The company has a 50-day simple moving average of $1.15 and a 200-day simple moving average of $1.10.

Insider Buying and Selling

In other news, major shareholder Eric Shahinian purchased 57,647 shares of the business’s stock in a transaction dated Wednesday, September 28th. The shares were bought at an average cost of $1.19 per share, for a total transaction of $68,599.93. Following the completion of the acquisition, the insider now directly owns 1,781,705 shares in the company, valued at approximately $2,120,228.95. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders purchased a total of 63,647 shares of company stock valued at $75,560 over the last three months. Company insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Pasithea Therapeutics

A hedge fund recently raised its stake in Pasithea Therapeutics stock. Vanguard Group Inc. lifted its stake in shares of Pasithea Therapeutics Corp. (NASDAQ:KTTAGet Rating) by 104.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 159,844 shares of the company’s stock after purchasing an additional 81,705 shares during the quarter. Vanguard Group Inc. owned 0.60% of Pasithea Therapeutics worth $201,000 as of its most recent SEC filing. 20.64% of the stock is owned by institutional investors.

About Pasithea Therapeutics

(Get Rating)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.

Further Reading

Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.